Provided By PR Newswire
Last update: Sep 7, 2022
GAITHERSBURG, Md., Sept. 7, 2022 /PRNewswire/ -- Novavax, Inc. ( Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Read more at prnewswire.comNASDAQ:NVAX (7/3/2025, 11:11:08 AM)
6.805
+0.04 (+0.67%)
Find more stocks in the Stock Screener